Dr Gavin Bendle


Dr Gavin Bendle is focused on developing engineered T cell therapy to treat cancer, with a particular focus on haematological malignancies.

Leukaemia and Lymphoma Research Bennett Senior Fellow, School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham

Email: g.bendle@bham.ac.uk

UoB profile

Background and Research focus

Dr Gavin Bendle leads a research group that aims to contribute towards the development of adoptive immunotherapy of cancer, with a particular focus on the engineering of T cell immunity to haematological malignancies through TCR gene transfer. His research is currently supported by Leukaemia and Lymphoma Research.

A key aim of Gavin’s current research is the selection and validation of TCRs for the clinical application of engineered T cell therapy of multiple myeloma. His research team is also using pre-clinical models to further optimize the efficacy and safety of engineered T cell therapy of cancer and using state-of-the-art tools to assess therapy induced changes in T cell immunity in cancer patients. As part of their research the Bendle group has established a number of collaborations with other groups both within the CIIC, nationally and internationally.


Adoptive T cell therapy; engineered T cell therapy; TCR gene transfer; tumour immunology; multiple myeloma; preclinical models.

Other activities

In addition to establishing an active research group Gavin is a member of the CIIC.  He also teaches on various postgraduate MSc programmes including Immunology & Immunotherapy and Clinical Oncology.


Linnemann C, Heemskerk B, Kvistborg P, Kluin RJ, Bolotin DA, Chen X, Bresser K, Nieuwland M, Schotte R, Michels S, Gomez-Eerland R, Jahn L, Hombrink P,Legrand N, Shu CJ, Mamedov IZ, Velds A, Blank CU, Haanen JB, Turchaninova MA, Kerkhoven RM, Spits H, Hadrup SR, Heemskerk MH, Blankenstein T, Chudakov DM, Bendle GM, Schumacher TN. High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med. 2013 Nov;19(11):1534-41.

Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN. Blockade of TGF-? signaling greatly enhances the efficacy of TCR gene therapy of cancer. J Immunol. 2013 Sep 15;191(6):3232-9.

Linnemann C, Schumacher TN, Bendle GM. T-cell receptor gene therapy: critical parameters for clinical success. J Invest Dermatol. 2011 Sep;131(9):1806-16.

Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen JB, Schumacher TN. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010 May;16(5):565-70, 1p following 570.

Bendle GM, Haanen JB, Schumacher TN. Preclinical development of T cell receptor gene therapy. Curr Opin Immunol. 2009 Apr;21(2):209-14

de Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM, Haanen JB, Schumacher TN. Requirements for effective antitumor responses of TCR transduced T cells. J Immunol. 2008 Oct 1;181(7):5128-36.

de Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, van Tinteren H, Mesman EM, Song JY, Schumacher TN. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol. 2008 Aug 15;181(4):2563-71.

Bendle GM, Xue SA, Holler A, Stauss HJ. A study of T cell tolerance to the tumor-associated antigen MDM2: cytokines can restore antigen responsiveness, but not high avidity T cell function. PLoS One. 2007 Apr 4;2(4):e353.

Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7934-9.

Bendle GM, Holler A, Pang LK, Hsu S, Krampera M, Simpson E, Stauss HJ. Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes. Cancer Res. 2004 Nov 1;64(21):8052-6.